Navigation Links
Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensing Program
Date:11/11/2008

ight-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

About Reliant Technologies: Reliant Technologies develops clinical solutions to rejuvenate aging and environmentally damaged skin. Reliant is dedicated to providing the most ergonomic and effective products to the global aesthetic marketplace. The company pioneered the development of fractional laser resurfacing that relies on novel high-speed scanning systems and the Intelligent Optical Tracking(R) system to produce safe and effective results with minimal recovery time. Reliant is based in Mountain View, Calif. The Fraxel(R) family of products, which includes the Fraxel re:pair(TM), Fraxel re:store(TM) and Fraxel re:fine(TM) laser systems, has quickly become the industry standard for fractional aesthetic skin treatment. Unlike laser devices of the past, Fraxel brand laser systems treat microscopic volumes of skin with each unique pulse, leaving the surrounding area intact for fast healing. Fraxel lasers have received multiple FDA clearances and have been found safe and effective in treating many areas of the face and body. The versatility of the product line ensures that patients can choose the best treatment for various stages of their lives as their skin care needs evolve.

Contacts: Kayla Castle

Investor Relations Manager

Palomar Medical Technologies, Inc.

781-993-2411


'/>"/>

SOURCE Palomar Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Palomar Medical Reports Financial Results for Third Quarter 2008
2. Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008
3. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
4. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
5. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
6. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
7. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
8. Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TIs Portfolio of Embedded Processors and Analog Products
9. Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008.
10. SpendLINK(TM) Enhancements Help Academic Medical Centers Easily Track Savings Opportunities
11. CPC Launches New Web Site Highlighting Medical, Research and Technical Panel, MedClose(TM) VCS Animated Video
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Continuing to meet the skin health needs ... addition of a new doctor and office in Grand ... skin care in Grand Rapids since 1980 is merging ... doctor, my passion is making sure my patients receive ... I’m better able to focus on my patients and ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 "My wife ... of a car accident," said one of two inventors ... strain in her shoulder and neck area. She tried ... reduced pain and pressure, assisting in comfort and providing ... patent-pending PILLOW CRADLE to support the head, neck and ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... August 2014: Transvenous lead extraction (TLE) is clinically successful ... from the European Lead Extraction ConTRolled (ELECTRa) registry presented ... by Dr Maria Grazia Bongiorni, chair of the registry,s ... cardiac implantable electronic devices (CIED) implant procedures has grown ... of complications has increased and leads are often the ...
(Date:8/30/2014)... August 30, 2014 Top10BestSEOHosting.com is ... researchers have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... current market. Also, they has announced that Bluehost ... , Hostgator, one of the Top 10 ... of cheap Windows hosting, and it offers rich ...
Breaking Medicine News(10 mins):Health News:Expanding Care at the Forefront of Dermatology 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2
... Approximately sixty-five state and local public health laboratories ... confirmatory testing of Human Influenza A H1N1 of Swine ... all swine flu specimens had to be sent to ... identifies specimens to the strain level.The rRT-PCR swine flu ...
... Approved Simponi is Expected to Achieve Strong ... a New Report from Decision ResourcesWALTHAM, Mass., ... the world,s leading research and advisory firms ... the availability of Amgen/Wyeth/Takeda,s Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe,s ...
... Justice grant creates federal-state-local partnership to help fight ... A sweeping $1.1 million U.S. Justice Dept. grant ... prosecution agency to help combat domestic violence and ... State,s Attorney,s Appellate Prosecutor,s office has hired two ...
... promise in study , , THURSDAY, April 30 (HealthDay News) ... multiple sclerosis (MS) drug may give patients more relief ... a new study. , In the study, which included ... selected to receive the steroid drug methylprednisolone in three ...
... After surgery to remove the head of the pancreas, ... in a lower rate of pancreatic fistula, according to ... Center. The research was published in the Journal ... performed as a randomized trial the gold standard ...
... up 266%, , ... Winston-Salem, NC ... that it is expanding its corporate and satellite offices to ... system, VerteLoc™. , , , , ,"We are essentially doubling ...
Cached Medicine News:Health News:Public Health Laboratories To Assume Primary Responsibility for Confirmatory Testing of Swine Flu 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 3Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Drug Combo May Relieve MS Symptoms 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:VGI Announces Expansion to Meet Surgeon Demand for the VerteLoc™ Spine Stabilization System 2
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Research and Development Trend Forecast of Pharmaceutical ... offering. Research and Development Trend Forecast ... , 2014-2018 mainly analyzes China,s ... status, supply & demand, competition landscape, and business performance ...
(Date:8/29/2014)... , Aug. 29, 2014   Vittamed Corporation , ... announced today that T. (Teo) Forcht Dagi ... the company,s Board of Directors. " Teo ... career in neurosurgery, medical innovation and venture capital," said ... extremely delighted to add his clinical, strategic, and entrepreneurial expertise ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely ... a generation ago are returning. Measles was declared eliminated ... in 2014 as of August 15—the highest incidence in ... public health department declared whooping cough a problem of ... are getting sick and dying from these preventable diseases—in ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), ... from two pre-clinical studies that,provide evidence ... combining nab-paclitaxel (ABRAXANE(R) for Injectable,Suspension (paclitaxel ... VEGF inhibitor drugs like,bevacizumab (Avastin(R)) at ...
... WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. ... first-time data from a pre-clinical study,evaluating ... nab-rapamycin,(ABI-009), an albumin-bound mTOR kinase inhibitor, ... Research (AACR) Annual Meeting held,April 14-18, ...
Cached Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 2Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 3Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: